Recent progress in the development of immune checkpoint inhibitors, such as anti-programmed cell death-1 (PD-1) antibodies and chimeric antigen receptor (CAR) T cells, holds promise for the treatment of various cancer types [8]. This evidence concerns the gene PDCD1 and cancer.